Stock PGEN PRECIGEN, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Precigen, Inc.

Equities

PGEN

US74017N1054

Delayed Nasdaq
Other stock markets
 12:01:40 30/04/2024 am IST 		5-day change 1st Jan Change
1.42 USD +0.71% Intraday chart for Precigen, Inc. +2.90% +5.97%
24/04 Precigen, Inc. to Present Late-Breaking Abstract for Pivotal Phase 2 Study Data for PRGN- 2012 AdenoVerse Immunotherapy CI
25/03 North American Morning Briefing : Tech in Focus on -2- DJ

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting
AQ
Precigen, Inc. to Present Late-Breaking Abstract for Pivotal Phase 2 Study Data for PRGN- 2012 AdenoVerse Immunotherapy
CI
Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th
PR
North American Morning Briefing : Tech in Focus on -2-
DJ
Precigen Shares Fall After Downgrade From JPMorgan
MT
JPMorgan Downgrades Precigen to Underweight From Neutral
MT
Precigen Reports Full Year 2023 Financial Results and Business Updates
AQ
Precigen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Transcript : Precigen, Inc., Q4 2023 Earnings Call, Mar 19, 2024
North American Morning Briefing : Stock Futures -2-
DJ
Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis
PR
Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th
PR
Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
PR
Precigen's Investigational RRP Therapy Gets Orphan Drug Designation in Europe
MT
Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission
PR
Precigen, Inc. Receives Orphan Drug Designation for PRGN- 2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission
CI
Transcript : Precigen, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 05:15 PM
Precigen Highlights Pipeline Updates to be presented at the 42nd Annual J.P. Morgan Healthcare Conference
AQ
Precigen to Present at the 42nd Annual J.P. Morgan Healthcare Conference
PR
Precigen to Participate in the JMP Securities Hematology and Oncology Summit
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PGEN Stock
  4. News Precigen, Inc.